Big Pharma Navigates Patent Cliffs and Medicare Pricing Scrutiny
What happened
Reports indicate that major pharmaceutical companies are facing pressure from patent expirations and market pricing demands. Johnson & Johnson recently raised its quarterly payout to $1.34 per share, marking its 64th consecutive annual increase. Pfizer's market pricing reflects a loss-of-exclusivity wave for drugs like Eliquis, Vyndaqel, and Ibrance, with growth anticipated later. Merck's CEO stated that the Keytruda 2028 patent cliff is manageable due to a pipeline valued at $70 billion.
From aol.com
Why it matters
The industry is under pressure from patent cliffs and pricing scrutiny, compounded by the impact of Medicare price setting and Part D redesign due to RFK Jr.'s appointment as HHS Secretary. While companies are defending payouts through diversified launches, genuine loss-of-exclusivity risk remains for several major players.
RFK Jr.'s appointment as HHS Secretary is creating pressure as Medicare price setting and Part D redesign impact the sales and operations of major pharmaceutical companies including Pfizer, Amgen, J&J, Merck, and Eli Lilly.
From aol.com
Who's involved
- PfizerFacing loss-of-exclusivity risk for key drugs like Eliquis and Ibrance.
- Johnson & JohnsonMaintaining a 64-year dividend streak while facing sector pressures.
- MerckManaging the Keytruda 2028 patent cliff with a large pipeline.
- Eli Lilly and CompanyA major pharmaceutical company impacted by Medicare pricing changes.
- AmgenA major biopharmaceutical company impacted by Medicare pricing changes.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- AbbVieSpeculative
Could face reduced revenue due to market pricing demands and sector risk.
- Jazz PharmaceuticalsSpeculative
May see costs increase related to defending against patent expirations.
- AmgenSpeculative
Could face pressure on sales volumes due to Medicare price setting.
- NovartisSpeculative
May experience changes in investment decisions due to industry-wide patent risk.
- Eli Lilly and CompanySpeculative
Could face challenges in maintaining market share due to pricing scrutiny.
Keep exploring
The entities involved
-
Pfizer
American multinational pharmaceutical and biotechnology corporation
-
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
-
Merck
public company in Indonesia
Related events
- Major pharmaceutical companies are competing for investment capital.
- FDA and Pfizer are seeking regulatory approval for their products.
- A group of major pharmaceutical companies, including AbbVie, Bristol-Myers Squibb, Amgen, Pfizer, Moderna, and Merck, are noted as peers operating in the highly regulated pharmaceutical sector.
- Pfizer's performance is being analyzed in comparison to the broader market.
- Johnson & Johnson is co-commercializing the prescription medicine IMBRUVICA with Pharmacyclics, a subsidiary of AbbVie.